98%
921
2 minutes
20
Systemic mastocytosis (SM) is a rare myeloproliferative neoplasm characterized by the clonal proliferation of mast cells in various organs, including the gastrointestinal (GI) tract. GI manifestations of SM, often non-specific, can lead to misdiagnosis, with symptoms overlapping those of common disorders such as achalasia, eosinophilic gastroenteritis, and inflammatory bowel disease. This case report details the diagnosis and management of an 83-year-old female with progressive dysphagia and weight loss, initially suspected to have achalasia. Following further investigation, SM was diagnosed based on histopathologic findings, including mast cell infiltration and CD117 and tryptase positivity, as well as molecular confirmation of the KIT D816V mutation. The case emphasizes the importance of a multidisciplinary diagnostic approach combining endoscopy, histopathology, and molecular testing to distinguish SM from other GI disorders. Early recognition, along with tailored treatment strategies, is essential for improving patient outcomes in SM with GI involvement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343066 | PMC |
http://dx.doi.org/10.1093/jscr/rjaf590 | DOI Listing |
Ann Hematol
September 2025
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
In a subset of patients with systemic mastocytosis (SM), an associated hematologic neoplasm (AHN) is identified. Most AHN are myeloid neoplasms, whereas lymphoid neoplasms are uncommon. We report on a 70-year-old female patient with bone marrow mastocytosis (BMM) associated with primary cutaneous follicle center lymphoma (PCFCL).
View Article and Find Full Text PDFJ Hematol
August 2025
Pathology Associates of Albuquerque (PAA), Albuquerque, NM 87106, USA.
Mast cell leukemia (MCL) is an exceedingly rare and aggressive variant of systemic mastocytosis (SM). MCL is classified as primary, occurring without prior mast cell (MC) disorders or secondary, from a pre-existing SM, and acute aggressive form with C-findings that indicate organ damage or chronic indolent form without organ damage. Of the cases, 60-65% are aleukemic with < 10% circulating MCs in the peripheral blood, and the rest of the cases are leukemic with > 10% MCs.
View Article and Find Full Text PDFHistopathology
September 2025
Department of Pathology, University of California, San Francisco, San Francisco, California, USA.
Aims: The use of the term 'histologic eosinophilic gastritis' (EoG) has been proposed for cases with ≥30 eosinophils/high power field (HPF) in five separate HPF and with no known associated causes of eosinophilia. This study evaluates the clinical presentation, pathologic characteristics of 'histologic eosinophilic gastritis'.
Methods And Results: Gastric biopsies with prominent mucosal eosinophils over 23 years were retrieved yielding 87 qualifying cases.
Ann Allergy Asthma Immunol
September 2025
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:
J Med Life
July 2025
Department of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania.
Systemic mastocytosis (SM) is a rare clonal mast cell disease characterized by heterogeneous clinical presentations and molecular features that vary across different regions; however, data from Central-Eastern Europe remain limited. This study aimed to describe the demographic, clinical, laboratory, and molecular characteristics of Romanian adults diagnosed with SM and followed at the national reference center for mast cell disorders in Bucharest, while also exploring real-world management patterns and outcomes. We conducted a retrospective observational study including 162 adult patients evaluated between January 2006 and March 2025 who met the 2022 World Health Organization criteria for SM.
View Article and Find Full Text PDF